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Bacterial infection and biofilm formation on the surface of biliary stents is believed to be one of the
main factors in stent occlusion. This study explored the role of the new reagent, bismuth dimercaprol,
in preventing bacterial adherence and bacterial biofilm formation on the surface of biliary stents.
Sterile porcine bile preparations, infected separately with Escherichia coli, Klebsiella pneumoniae,
Enterobacter, and Enterococcus, were used as the perfusion media in an in vitro perfusion system.
The bacterial growth in the media and the bacterial adherence on the surface of stents were tested when
different concentrations of bismuth dimercaprol were used in the perfusion media. BisBAL (5 µM)
did not inhibit the growth of any of the tested bacterial species. It did, however, significantly decrease
the amount of bacteria adhering to the surface of stents for all bacterial strains except Escherichia
coli. Bismuth dimercaprol (20 µM) significantly inhibited the growth of Escherichia coli, Klebsiella
pneumoniae, and Enterobacter and, thereby, significantly decreased the amount of these bacteria
adhering to the surface of stents. The unique bactericidal and anitbiofilm activities of bismuth thiols
might contribute to delaying the process of biliary stent occlusion if the effective concentrations of
bismuth thiols could be delivered to the target sites. The feasibility of this application of bismuth
thiols deserves further investigation.
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Biliary endoprosthesis placement is a common procedure
in palliating malignant or benign obstruction of bile tracts,
but stent occlusion remains a major problem in this treat-
ment. It is believed that the deposition of calcium salts
due to the biochemical activities of bacterial enzymes in
the biofilm on the surface of the stents and reflux of in-
testinal contents into stents are the two main mechanisms
of stent occlusion (1–4). Reflux of intestinal contents into
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bile tracts or stents is a prevalent phenomenon when stents
are placed across the sphincter of Oddi (32). Besides the
direct mechanical blockage caused by large food debris,
these small food materials or other tiny amorphous food
debris may contribute to stent occlusion by trapping cal-
cium salt deposits in bile, promoting bacterial infection
in the stents, or participating in the buildup of sludge. For
this mechanism, designing a new stent may be the only so-
lution. For the first mechanism, prevention of bacterial in-
fection and biofilm formation may be of benefit. However,
so far no reagents have proven to be satisfactory (5–7).
Due to the antiseptic, astringent, protective, antacid, an-
tisecretory, and local gastrointestinal properties of bismuth
(the site of action is within the gastrointestinal lumen),
bismuth-containing compounds have been widely used in
clinical practice, such as for treatment of dyspepsia and
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Fig 1. A stent perfusion system in vitro. Five straight, 10-F, 7-cm-long polyethylene stents
were connected in tandem in each perfusion circle. Porcine bile was collected and used as the
basic perfusion medium. Medium containers were placed in a water bath at 37◦C. Stents were
sealed in sterile pouches. Bile flow rate in each perfusion circle was adjusted to 1 ml/min. The
pump has multiple channels to drive the perfusion circles.
diarrhea and for the eradication of Helicobacter pylori in
the stomach (8–12). Recently, the antibacterial properties
of bismuth have been greatly enhanced, up to 1000-fold,
through combination with certain lipophilic thiol com-
pounds, thereby significantly enhancing its potency and
versatility as an antibacterial agent (13). A series of re-
ports from Domenico et al. demonstrated the unique ef-
fects of bismuth thiols compounds at low concentrations
on bacterial virulent factors such as exopolysaccharide
expression and bacterial biofilm formation (14–16). Con-
sidering the increased antibacterial activities, specific role
of antibiofilm at low concentrations, local gastrointestinal
property, and relatively low toxicity, we think that bismuth
thiols may be a choice for treating bacterial infection and
biofilm formation involved in biliary stent occlusion. To
explore this possibility and feasibility, this study utilized
bismuth-2,3-dimercaptopropanol (BisBAL) as a sample to
test the effect of bismuth thiols on the common bacterial
strains that attach to biliary stents. This report primarily
documents the role of BisBAL in inhibiting the growth of
tested bacteria in bile and their effect on the bacterial ad-
herence to the surface of stents in an in vitro bile perfusion
system.
MATERIALS AND METHODS
Bile Perfusion System. A flow cell system (Stovall Life Sci-
ence, Greensboro, NC) was modified and employed in this study.
Five straight, 10-F, 7-cm-long polyethylene stents (Wilson–
Cook Medical, Winston–Salem, NC) were connected in tandem
in each perfusion circle instead of the flow cells, indicated in
Figure 1. Porcine bile was collected following the established
procedure in our laboratory (17) and used as the basic perfu-
sion medium. Medium containers were placed in a water bath
at 37◦C. Stents were sealed in sterile pouches. Bile flow rate in
each perfusion circle was adjusted to 1 ml/min in view of the
bile flow rate in the bile duct of human (18).
Previous studies from our laboratory and others indicated that
four bacterial species, Escherichia coli, Klebsiella pneumoniae,
Enterobacter, and Enterococcus, are the most common microor-
ganisms involved in stent infection (19, 20). One strain of each
species was used in this study, which were cultured and isolated
from the biliary stents that were rermoved from patients. Bac-
teria were inoculated in bile at about 107–108 colony-forming
units (CFU)/ml (21, 22).
For each bacterial strain, four bile reservoirs (200 ml each)
with additional 0, 5, 10, and 20 µM bismuth BisBAL, were
pooled separately in this perfusion system. Bacterial adher-
ence to stent inner surfaces was measured by the plate-
count method as described below, at 2, 6, 12, 20, and 24 hr,
respectively.
Preparation of BisBAL. BisBAL was prepared in liquid
form according to the method of Domenico et al. (14), by
combining bismuth nitrate and dimercaprol (both from Sigma
Chemical Co., St. Louis, MO) at a 2:1 molar ratio in propylene
glycol. BisBAL was directly diluted into the perfusion medium
to the required concentrations.
Demonstration of Bacterial Adherence on Stents. The
amount of bacteria adhering to the surfaces of stents was mea-
sured using the previously established method (19). In brief, the
stents were removed individually at each time point and rinsed
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with 5 ml sterile phosphate-buffered saline (PBS) to remove
nonadherent bacteria. The stents were cut into about 0.2-cm-long
portions, and then ultrasonicated in 2 ml PBS to free the adher-
ent bacteria. Serial dilutions of this bacterial suspension were
made and cultured on nutrient agar. The results of the overnight
cultures were recorded as colony forming units per milliliter of
bacterial suspension.
In addition, the amount of bacteria in bile was also measured
at each time point by the plate-count method.
Measurement of Slime Products of Bacteria. Most bacteria
contain some sort of a polysaccharide layer outside of the cell
wall or outer membrane. These extracellular polymeric materials
are generally called glycocalyx, but may also be referred to as the
bacterial slime layer or exopolysaccharides. To test the ability
of the bacterial species included in this study to produce these
slime materials, all bacteria were cultured in both nutrient broth
and bile for 24 hr. Then cultures of bacteria were diluted 1:100
with fresh nutrient broth and 1:50 with bile. Individual wells of
sterile, polystyrene, 96-well, flat-bottomed tissue culture plates
were filled with 0.2-ml aliquots of the diluted culture. The tissue
culture plates were incubated for 24 hr at 37◦C. The contents of
each well were gently aspirated by tipping the plate and placing
the aspirator tip in the lowest corner of the well. The wells were
washed two times with 0.2 ml of PBS. Adherent organisms were
fixed in place with Bouin fixative (23) and stained with Hucker
crystal violet. Excess stain was rinsed off by placing the plate
under running tap water. After drying, the optical density (OD)
of stained adherent bacterial films was read at a wavelength of
570 nm with a Spectra Max 250 plate reader (Global Medical
Instrumentation, Inc., Albertville, MN).
Statistical Analysis. The amount of adherent bacteria on the
surfaces of stents among different groups was compared us-
ing repeated-measures one-way analysis of variance. The dif-
ferences in slime production of bacteria in different media were
analyzed by the nonparametric test. P values less than 0.05 were
considered significant for all the tests. All statistical calculations
were performed with the use of Prism3.0 (GraphPad Software,
Inc., San Diego, CA).
RESULTS
The ability of each bacterial strain to produce slime
was tested in both nutrient broth and porcine bile. The
results are shown in Figure 2. When bacteria were cul-
tured in the nutrient broth, the strain of Escherichia coli
was the least slime-productive and Enterobacter was the
most slime-productive among the four bacterial species,
while the strain of Enterococcus produced the least slime
but Klebsiella pneumoniae produced the most slime when
bacteria were cultured in the bile medium.
The growth curves of bacteria in bile with different con-
centrations of BisBAL are shown in Figure 3. BisBAL
at 5–10 µM did not inhibit the growth of Escherichia
coli, Enterobacter, and Enterococcus, but 10 µM BisBAL
inhibited the growth of Klebsiella pneumoniae. BisBAL
at 20 µM was very effective in inhibiting growth for
E. coli, Klebsiella pneumoniae, and Enterobacter but not
Enterococcus.
Fig 2. The slime production of each bacterial species growing in nutrient
broth (dark bars) and porcine bile (light bars) for 24 hr. (a) Escherichia
coli; (b) Klebsiella pneumoniae; (c)Enterobacter; (d) Enterococcus.
Bacteria adhering to microtiter plates were processed and measured for
absorbance at 570 nm. Values are means ± standard deviations.
The data in Figure 4a show that the amount of
Escherichia coli adhered to the surface of stents in the
group without BisBAL was significantly higher than that
in the group with 20 µM BisBAL (P < 0.05). However,
no difference in bacterial adhesion was found among the
groups with 0, 5, and 10 µM BisBAL (P > 0.05). When
bile was inoculated with Klebsiella pneumoniae as a per-
fusion medium, as demonstrated in Figure 4b. The addi-
tion of 5 µM BisBAL caused a very remarkable reduction
in Klebsiella pneumoniae adherence to the surface of the
stents. At 10 µM , BisBAL in bile did not cause a greater
reduction of bacterial adherence to the surface of stents
than at 5 µM . However, 20 µM BisBAL in bile decreased
bacterial adherence to the surface of the stents even fur-
ther. Similarly, less bacterial adhesion of Enterobacter was
seen with higher concentrations of BisBAL, as indicated
in Figure 4c. When Enterococcus was tested, as shown
in Figure 4d, the amount of bacteria adhering to the stent
surface was less in the group with 5 µM BisBAL than the
group without BisBAL. However, adding more BisBAL
to the bile in the other two groups did not further reduce
the number of bacteria adhering to the surface of stents.
DISCUSSION
Under normal conditions, duodenal refluxing to the
common bile duct and pancreatic duct do not usually oc-
cur, so bile and pancreatic juice are sterile (24, 25). In the
treatment of malignant or benign obstructive jaundice for
inoperable cases, it is conventional to place a plastic bil-
iary stent across the sphincter of Oddi. As a result of the
stenting across the sphincter of Oddi, low pressure in the
common bile duct and breakage of the bacterial barrier
facilitate the reflux of intestinal contents and ascending
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Fig 3. Growth curves of bacteria in bile with BisBAL at different concentrations: 0 µM(∗), 5 µM(•), 10 µM(), and 20 µM(0). (a) Escherichia
coli; (b) Klebsiella pneumoniae; (c) Enterobacter; (d) Enterococcus. Bacteria were measured with the plate-count method and are expressed as
colony forming units per milliliter of bacterial suspension. Values are means of double determinations.
bacterial infection (26, 27). While the stenting procedure
is performed, bacteria in the intestinal tract may also be
brought into the bile duct. Moreover, when a plastic stent
is placed in the bile duct, the bacteria in bile easily at-
tach, colonize, and grow on the inner surface of the stent.
Since most bacterial species can produce slime, a bacte-
rial biofilm is often formed on the stent surface. Persistent
existence of bacterial biofilm and consequent deposition
of salts for bacterial enzymatic activities result in the final
failure of most biliary stenting treatments.
Bacterial biofilm is a special microorganism commu-
nity, in which bacteria respond differently to antimicro-
bials compared to suspended bacteria. Biofilm bacteria
may express some genes that generate antimicrobial resis-
tance. Biofilms may exhibit heterogeneity such as gradi-
ents in physiology where slower-growing organisms may
be more resistant to antimicrobials. Bacteria are usually
surrounded by the extracellular matrix and biofilms in
the field may accumulate inorganic or organic substances
from the surrounding medium; as a result, antimicrobials
may not fully penetrate a biofilm (28–30). Therefore, to
prevent the complications and improve the effectiveness of
biliary stents, it is critical to control bacterial infection be-
fore bacterial biofilm has formed on the surface of stents.
Some strategies, such as preventing bacteria from enter-
ing the bile duct, killing the suspended bacteria in bile, or
inhibiting initial bacterial adherence, could be taken. This
study showed the particular effect of BisBAL at different
concentrations on the tested bacteria in vitro. Those spe-
cific functions of BisBAL may be employed in preventing
bacterial biofilm formation on the surface of stent.
The bactericidal effect of bismuth thiols in the bile or in
the biliary tract system has never been investigated. This
study addressed the information. The results showed that
BisBAL at 10 µM significantly decreased the amount of
Klebsiella pneumoniae growing in bile, the effects of Bis-
BAL at 20 µM are more intensive, and it largely reduced
the amount of another two bacterial strains: Escherichia
coli and Enterobacter. The activities of bismuth thiols fa-
vor a high temperature and pH value. In our study the pH
value of porcine bile was approximately 7.0 (6.90 ± 0.48),
and the system temperature was set at 37◦C to simulate
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Fig 4. Bacteria adhering to the surface of stents when stents were perfused with bile with different concentrations of BisBAL:
0 µM(∗), 5 µM(•), 10 µM(), and 20 µM(0). (a) Escherichia coli; (b) Klebsiella pneumoniae; (c) Enterobacter; (d) Enterococcus. Bacteria
were measured with the plate-count method and are expressed as colony forming units per milliliter of bacterial suspension.
the human body temperature. The above results indicated
that BisBAL was functioning in porcine bile at the ex-
perimental temperature in vitro. Since the pH value and
compositions of porcine bile are similar to those of hu-
man bile, we believe that BisBAL could function as a
bactericidal reagent against certain bacteria in the human
biliary system in vivo if it could be supplied at the effective
concentrations.
Yet a more interesting finding from our study was that
BisBAL at low concentration (5 µM) reduced Klebsiella
pneumoniae, Enterobacter, and Enterococcus adherence
to the surface of biliary stents in vitro. Previous studies
have demonstrated that subinhibitory levels (3–5 µM)
of BisBAL can inhibit expression of glycocalyx or ex-
opolysaccharide in Klebsilla pneumoniae, Staphylococca,
and Pseudmonas aeruginosa in certain culture broths (14–
16, 31). These bacterial surface structures, such as cap-
sules, flagella, and fimbriae (or pili), as well as slime,
along with the physical properties of substratum surfaces,
are the most important factors for bacterial attachment
and adherence to a surface (28). It is unsure whether the
effect of BisBAL at a low concentration (5 µM) against
bacterial adherence to the surface of biliary stents in this
study is through inhibition of the expression of glyco-
calyx or exopolysaccharide as in other culture media in
previous studies. This is because bacteria might present
different biological behaviors in different culture media.
As demonstrated by our results, the four bacterial strains
changed their ability to produce slime when the culture
medium was switched from nutrient broth to porcine bile.
Moreover, BisBAL may have different effects on the same
bacteria in different environments. The interactions among
BisBAL, bacteria, and bile compositions are complicated.
Despite the uncertain mechanism, this study demonstrated
with certainty that BisBAL at a low concentration (5 µM)
could inhibit the adherence of certain bacteria to the inner
surface of biliary stents, which might contribute to control
biofilm formation in the initial process.
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As demonstrated in this study, 5 µM BisBAL did not
affect the adhesion of the tested E. coli strain to the surface
of stents and 20 µM BisBAL did not inhibit the growth
of tested Enterococcus. As reported in one study (20),
a lot of bacterial species and strains have been isolated
from biliary stents removed from patients. To ensure that
bismuth thiols are effective and broad-spectrum enough
as antibacterial reagents against the bacteria involved in
biofilm formation on biliary stents, further work needs to
be done, including tests with more bacterial species and
strains and with wider ranges of concentration of bismuth
thiols. Routes of application of bismuth thiols for control-
ling bacterial infection in biliary stents, such as coating
the stent surface with special materials with bismuth thi-
ols incorporated, need to be tested in vivo. In short, the
mechanism of bismuth thiols to prevent bacterial biofilm
formation on the surface of biliary stents and the feasibil-
ity of applying it to reduce the complications of biliary
stenting need to be investigated further.
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